Comparison of diagnostic and treatment processes among pediatric and adolescents and young adults’ populations suffering from acute lymphoblastic leukemia and lymphomas

Introduction Acute lymphoblastic leukemia (ALL) and lymphomas affect both pediatric and adult populations, therefore, they might be treated by pediatric or adult centers.It has been proven that the prognosis among adolescents and young adults (AYA) is poorer than among children, which remains a subject of research. Many factors are suspected to affect the diagnostic and treatment processes in adolescents and young adults, one of them being the organization of the healthcare system.The aimof the studywas to compare the time intervals between different events on disease trajectory in pediatric and AYA groups suffering from ALL and lymphomas. Methods We collected data on 81 patients diagnosed with ALL (50 children and 31 AYAs) and 100 patients diagnosed with lymphomas (50 children and 50 AYAs). Statistical analysis was performed in order to compare the groups. Results The results confirmed the hypothesis that the duration of the diagnostic process differs significantly between groups. For patients with ALL, the analyzed time intervals were significantly shorter in the pediatric group than in the AYA group: first contact with a GP - admission to Hematology Department (2 vs. 5 days; pvalue= 0.004), first contact with a GP - treatment (6 vs. 12 days, p-value=0.001), diagnosis - treatment (1 vs. 3 days, p-value=0.003). In the case of patients suffering from lymphomas, the results were similar. The analyzed time intervals were significantly shorter in the pediatric group than in the AYA group: first contact with a GP- diagnosis (21 vs. 40.5 days, p-value<0.0001), first contact with a GP - treatment (27 vs. 65 days, p-value<0.0001). Trend analysis showed that the longer patients had presented symptoms before contacting the primary care physician, the longer they waited for the beginning of treatment both in ALL and lymphomas groups (p-values=0.0129 and 0.0038 respectively). Discussion As the diagnostic and treatment processes are longer for AYA patients, actions must be undertaken in order to ensure equality and improve the healthcare system in Poland and possibly other countries.

[1]  Y. Nieto,et al.  Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective , 2022, Cancers.

[2]  O. Husson,et al.  Adolescent and Young Adult (AYA) Cancer Survivorship Practices: An Overview , 2021, Cancers.

[3]  K. Derwich,et al.  Acute Lymphoblastic Leukemia in Adolescents and Young Adults: A Polish Perspective. , 2021, Journal of adolescent and young adult oncology.

[4]  L. Soanes,et al.  Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE) , 2021, ESMO open.

[5]  A. Jemal,et al.  Cancer statistics for adolescents and young adults, 2020 , 2020, CA: a cancer journal for clinicians.

[6]  P. Nathan,et al.  The effect of adopting pediatric protocols in adolescents and young adults with acute lymphoblastic leukemia in pediatric vs adult centers: An IMPACT Cohort study , 2019, Cancer medicine.

[7]  J. Richman,et al.  Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[8]  K. Dunleavy,et al.  Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective. , 2018, Blood.

[9]  A. Baruchel,et al.  Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children? , 2018, Blood.

[10]  J. Malvar,et al.  A prospective, observational cohort study comparing cancer clinical trial availability and enrollment between early adolescents/young adults and children , 2018, Cancer.

[11]  J. Sandlund,et al.  Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. , 2016, Hematology. American Society of Hematology. Education Program.

[12]  D. Deapen,et al.  Case‐linked analysis of clinical trial enrollment among adolescents and young adults at a National Cancer Institute‐Designated comprehensive cancer center , 2015, Cancer.

[13]  M. Stevens,et al.  Trends in survival for teenagers and young adults with cancer in the UK 1992–2006 , 2015, European journal of cancer.

[14]  Ahmedin Jemal,et al.  Childhood and adolescent cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[15]  L. Harlan,et al.  Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Bloomfield,et al.  What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. , 2008, Blood.

[17]  A. Bleyer,et al.  Cancer in 15- to 29-year-olds by primary site. , 2006, The oncologist.

[18]  P. Sonneveld,et al.  [Adolescents with acute lymphatic leukaemia achieve significantly better results when treated following Dutch paediatric oncology protocols than with adult protocols]. , 2005, Nederlands tijdschrift voor geneeskunde.

[19]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[20]  S. Gomez,et al.  Adoption of pediatric‐inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population‐based study , 2017, Cancer.

[21]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[22]  J. Sandlund Should adolescents with NHL be treated as old children or young adults? , 2007, Hematology. American Society of Hematology. Education Program.